Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment
Palatin Technologies Inc (NYSE:PTN) has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry…
UPDATE: Moderna Says ‘Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all variants tested’ Including Beta, Kappa, Eta And Delta Variant
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new results from in vitro neutralization studies of sera from individuals vaccinated
Moderna Provides Clinical Update On Neutralizing Activity OfCOVID-19 Vaccine On Emerging Variants Including Delta Variant
Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine
Serum neutralization assays performed on emerging variants
Vericel, MediWound Report That FDA Has Determined Application For MexoBrid Cannot Be Approved In Its Present Form
MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter
Walmart Highlights Launch Of Private Brand Analog Insulin
Walmart's exclusive ReliOn™ NovoLog® vials and FlexPens® will save customers 58% to 75% off the cash price of branded insulin products.
Walmart announced the launch of the
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 28)
TRACON Pharmaceuticals Announces Orphan Drug Designation For Envafolimab In Soft Tissue Sarcoma
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders
Abiomed Receives FDA Pre-Market Approval For Impella RP With SmartAssist
Abiomed's (NASDAQ:ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart
VBI Vaccines Announces Initial Phase 1 Data For Its eVLP Vaccine Candidate Against COVID-19; Says After Two Doses, VBI-2902a ‘induced neutralization titers in 100% of participants’
The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years
After two doses, VBI-2902a induced neutralization